All In Biotech

Free tool

FAERS Monitor: Merilog

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761325 or its brand name (Merilog, Insulin Aspart-Szjj). Reports on generic versions are filed under their own applications.

Reports

10

Serious

2

20% of reports

Hospitalization

2

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective2
  • off label use2
  • blood glucose abnormal1
  • blood glucose increased1
  • hyperhidrosis1
  • hyperthyroidism1
  • hypoglycaemia1
  • hypoglycaemic coma1
  • incorrect route of product administration1
  • intentional overdose1
  • intentional product misuse1
  • loss of consciousness1
  • poor quality product administered1
  • product dispensing error1
  • product dispensing issue1

Reports by year received

View as table
YearReports
20252
20268

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,149 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hypoglycaemic coma1730.0113.7181
product dispensing issue1491.876.6122
poor quality product administered1199.631.149
hyperthyroidism1145.322.635
incorrect route of product administration1122.719.130
blood glucose abnormal1113.917.728
product dispensing error196.615.023
hypoglycaemia143.46.810
intentional overdose132.85.17
intentional product misuse124.03.75
loss of consciousness116.42.63
hyperhidrosis116.32.53
blood glucose increased111.21.72
off label use24.81.43
drug ineffective23.20.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.